Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acoramidis. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR known ✓ | P02766 | 6/20 | 0.98 |
| ▸ | ALB | P02768 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acoramidis SCHEMBL20475239 | 1.00 | TTR (0.98) | TTRALBSMN1; SMN2MAPTHSD17B10 | |
| Acoramidis SCHEMBL15816954 | 0.99 | TTR (1.00) | TTRALBSMN1; SMN2MAPTHSD17B10 | |
| Acoramidis SCHEMBL29350324 | 0.99 | TTR (1.00) | TTRALBSMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL15832081 | 0.97 | TTR (0.95) | TTRALBSMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL24953188 | 0.90 | TTR (0.83) | TTRALBSMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL17525272 | 0.90 | TTR (0.83) | TTRALBSMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL15816998 | 0.89 | TTR (0.81) | TTRALBSMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL17522783 | 0.89 | TTR (0.81) | TTRALBSMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL15816962 | 0.88 | TTR (1.00) | TTRALBSMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL17522791 | 0.87 | TTR (0.94) | TTRALBSMN1; SMN2MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539290-B2 | Formulations of AG10 | Eidos Therapeutics, Inc. (US) | 2026-02-03 | — | — | US | claimed |
| WO-2025235883-A1 | ACORAMIDIS FOR USE IN THE TREATMENT OF RENAL DYSFUNCTION | Eidos Therapeutics, Inc. (US) | 2025-11-13 | — | — | WO | claimed |
| EP-4647068-A2 | FORMULATIONS OF AG10 | Eidos Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250313534-A1 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | ALTER DOMUS (US) LLC, AS COLLATERAL AGENT | 2025-10-09 | — | — | US | claimed |
| US-20250057811-A1 | FORMULATIONS OF AG10 | ALTER DOMUS (US) LLC, AS COLLATERAL AGENT | 2025-02-20 | — | — | US | claimed |
| US-20250041276-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | ALTER DOMUS (US) LLC, AS COLLATERAL AGENT | 2025-02-06 | — | — | US | claimed |
| WO-2023052652-A1 | CRYSTALLINE FORM OF ACORAMIDIS HYDROCHLORIDE | SANDOZ AG (CH) | 2023-04-06 | — | — | WO | claimed |
| CN-122056844-A | AG10 formulations | 文涵治疗有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260097014-A1 | FORMULATIONS OF AG10 | EIDOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12539290-B2 | Formulations of AG10 | Eidos Therapeutics, Inc. (US) | 2026-02-03 | — | — | US | disclosed |
| WO-2025235883-A1 | ACORAMIDIS FOR USE IN THE TREATMENT OF RENAL DYSFUNCTION | Eidos Therapeutics, Inc. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4647068-A2 | FORMULATIONS OF AG10 | Eidos Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250313534-A1 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | ALTER DOMUS (US) LLC, AS COLLATERAL AGENT | 2025-10-09 | — | — | US | disclosed |
| CN-110381940-B | AG-10 preparation method, intermediate and salt thereof | 文涵治疗有限公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2023052652-A1 | CRYSTALLINE FORM OF ACORAMIDIS HYDROCHLORIDE | SANDOZ AG (CH) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023052652-A1 | CRYSTALLINE FORM OF ACORAMIDIS HYDROCHLORIDE | SANDOZ AG (CH) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023052652-A1 | CRYSTALLINE FORM OF ACORAMIDIS HYDROCHLORIDE | SANDOZ AG (CH) | 2023-04-06 | — | — | WO | disclosed |
| US-20220313661-A1 | FORMULATIONS OF AG10 | PHOENIX TISSUE REPAIR, INC. | 2022-10-06 | — | — | US | disclosed |
| US-11260047-B2 | Formulations of AG10 | Eidos Therapeutics, Inc. (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220041558-A1 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | Ferro Therapeutics, Inc. | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220313661-A1 | FORMULATIONS OF AG10 | ATXN10, RAB10, HDAC10 | TTR 410/4885ALB 317/4885SMN1; SMN2 3021/4885 |
| US-20220041558-A1 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | UGT1A10, SAMM50, AGL | TTR 109/4885ALB 43/4885SMN1; SMN2 2025/4885 |
| US-12539290-B2 | Formulations of AG10 | RPLP0, ATXN10, USP10 | TTR 159/4885ALB 130/4885SMN1; SMN2 1962/4885 |
| US-20250041276-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | TTR, TMSB10, APOB | TTR 1/4885ALB 4/4885SMN1; SMN2 374/4885 |
| US-20250313534-A1 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | UGT1A10, SAMM50, AGL | TTR 109/4885ALB 43/4885SMN1; SMN2 2025/4885 |
| US-20250057811-A1 | FORMULATIONS OF AG10 | ATXN10, RAB10, HDAC10 | TTR 410/4885ALB 317/4885SMN1; SMN2 3021/4885 |
| US-11260047-B2 | Formulations of AG10 | ATXN10, RAB10, HDAC10 | TTR 410/4885ALB 317/4885SMN1; SMN2 3021/4885 |
| US-20260097014-A1 | FORMULATIONS OF AG10 | ATXN10, STARD10, S100A10 | TTR 367/4885ALB 235/4885SMN1; SMN2 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.